SCHEMBL21612040

SCHEMBL21612040

CC(C)Oc1ccc(-c2ncc(CNc3cc(Cl)nc(C(F)(F)F)c3)s2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 3/20 0.61
▸ CYP2C9 P11712 2/20 0.61
▸ KCNH2 Q12809 1/20 0.48
▸ MAPT P10636 7/20 0.37
▸ SMN1; SMN2 Q16637 4/20 0.37
▸ ALPL P05186 2/20 0.36
▸ ALPI P09923 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ TP53 P04637 3/20 0.35
▸ HDAC3 O15379 2/20 0.35
▸ HDAC1 Q13547 2/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ FFAR1 O14842 1/20 0.35
▸ PTGS2 P35354 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21614696 0.90 CYP2C19 (0.54) CYP2C19CYP2C9KCNH2MAPTTP53
SCHEMBL21612041 0.88 CYP2C19 (0.79) CYP2C19CYP2C9KCNH2S1PR1
SCHEMBL21614697 0.87 CYP2C19 (0.55) CYP2C19CYP2C9KCNH2MAPTSMN1; SMN2
SCHEMBL21611987 0.86 CYP2C19 (0.49) CYP2C19CYP2C9KCNH2MAPTSMN1; SMN2
SCHEMBL21614772 0.85 CYP2C19 (0.75) CYP2C19CYP2C9KCNH2HDAC3HDAC1
SCHEMBL23611234 0.84 CYP2C19 (0.51) CYP2C19CYP2C9KCNH2MAPTSMN1; SMN2
SCHEMBL30062377 0.84 CYP2C19 (0.51) CYP2C19CYP2C9KCNH2MAPTSMN1; SMN2
SCHEMBL23611317 0.84 CYP2C19 (0.52) CYP2C19CYP2C9KCNH2MAPTSMN1; SMN2
SCHEMBL23611535 0.84 CYP2C19 (0.52) CYP2C19CYP2C9KCNH2MAPTSMN1; SMN2
SCHEMBL30060450 0.84 CYP2C19 (0.52) CYP2C19CYP2C9KCNH2MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353606-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-11-18 — — US disclosed
EP-3818045-A1 PQSR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-05-12 — — EP disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353606-A1 PqsR INVERSE AGONISTS QRFPR, P2RY11, QARS1 CYP2C19 1824/4885CYP2C9 2997/4885KCNH2 2343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback